- About ImmunoMet · Founded 2015
Built on a Singular Insight About Cancer Metabolism
ImmunoMet Therapeutics was founded in 2015 as a spin-off from Hanall Biopharma in Korea, with a focused mandate: develop lixumistat into a clinical cancer drug addressing one of oncology’s most stubborn challenges — acquired resistance to existing treatments.
- Founding Story
A Spin-Off Built Around a Precise Scientific Bet
ImmunoMet was founded with a singular focus: develop lixumistat into a validated clinical asset targeting oxidative phosphorylation in cancer. Since 2015, the company has raised approximately $39 million and advanced lixumistat through multiple Phase 1 studies and into an ongoing Phase 1b/2a trial at MD Anderson Cancer Center.
The company works with a network of specialist CROs and clinical partners — each contributing world-class expertise across chemistry, manufacturing, clinical operations, legal, and regulatory functions.
Founded
Spin-off from Hanall Biopharma, Korea
Total Capital Raised
2015 to present
Headquarters
- Get in Touch
Recent Updates
January 2025 · San Francisco
Interim data from the PDAC trial at MD Anderson presented at the ASCO Gastrointestinal Cancers Symposium, January 2025.
Conference
July 2025 · Barcelona
Updated Phase 1b/2a data presented at the ESMO Gastrointestinal Cancers Symposium, July 2025.
Conference
June 22–25, 2026 · San Diego
ImmunoMet will present updated data and investment thesis at BIO International 2026, San Diego Convention Center.
upcoming
